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Uncoupling protein-3 (UCP3) is a member of the mitochon-
drial carrier family expressed preferentially in skeletal mus-
cle and heart. It appears to be involved in metabolic handling
of fatty acids in a way that minimizes excessive production of
reactive oxygen species. Fatty acids are powerful regulators
of UCP3 gene transcription. We have found that the role of
peroxisome proliferator-activated receptor- (PPAR) on the
control of UCP3 gene expression depends on the tissue and
developmental stage. In adults, UCP3 mRNA expression is
unaltered in skeletal muscle from PPAR-null mice both in
basal conditions and under the stimulus of starvation. In con-
trast,UCP3mRNAisdown-regulated inadultheartboth in fed
and fasted PPAR-null mice. This occurs despite the in-
creased levels of free fatty acids caused by fasting in PPAR-
nullmice. In neonates, PPAR-nullmice show impairedUCP3
mRNA expression in skeletal muscle in response to milk in-
take, and this is not a result of reduced free fatty acid levels.
ThemurineUCP3promoter is activatedby fattyacids through
either PPAR or PPAR but not by PPAR or retinoid X re-
ceptor alone. PPAR-dependent activation could be a poten-
tial compensatory mechanism to ensure appropriate expres-
sion of UCP3 gene in adult skeletal muscle in the absence of
PPAR. However, among transcripts from other PPAR and
PPAR target genes, only those acutely induced by milk in-
take in wild-type neonates were altered in muscle or heart
from PPAR-null neonates. Thus, PPAR-dependent regula-
tion is required for appropriate gene regulation of UCP3 as
part of the subset of fatty-acid-responsive genes in neonatal
muscle and heart. (Endocrinology 147: 4695–4704, 2006)
UNCOUPLING PROTEIN-3 (UCP3) is a mitochondrialprotein similar to the thermogenic UCP1 protein
present in brown adipose tissue. UCP3 is expressed prefer-
entially in skeletal muscle and brown fat and to a minor
extent in heart and white adipose tissue (1). Although this
protein appears to be capable of lowering mitochondrial
membrane potential, its precise biological function is a mat-
ter of debate. Various reports suggest that it can play a role
in mitochondrial fatty acid metabolism (2) as well as in the
control of mitochondrial reactive oxygen species production
(3). In any case, UCP3 appears to be involved in the regu-
lation of biological processes associated with mitochondrial
energy metabolism, and accordingly, UCP3 gene expression
is tightly regulated under physiological conditions associ-
ated with major changes in fuel metabolism, such as the early
neonatal period (4).
Birth leads to a major change in nutrient use for energy
metabolism. In rodents, there is a sudden change after de-
livery from a glucose-based fetal nutrition to a lipid-based
diet coming from milk intake. Thus, the metabolic adaptation
to birth requires the induction of hepatic gluconeogenesis to
maintain glycemia and the activation of lipid oxidation in
most tissues to use this fuel for energy metabolism. In neo-
nates, extrahepatic tissues such as skeletal muscle or heart
switch from the use of glucose to the use of fatty acids and
ketone bodies as the major fuel source instead of glucose (5).
These metabolic events, which resemble those elicited by
fasting in adults, are induced in neonates by the fed state,
because they result from the sudden imbalance between
glucose and lipid availability in the transition from the fetal
to the neonatal period.
UCP3 gene expression is very low in skeletal muscle dur-
ing the fetal period, and it is dramatically induced after birth
under the stimulus of the rise of circulating free fatty acids
(FFA) because of the initiation of milk intake (6). In fact, FFA
levels determine UCP3 gene expression in skeletal muscle
regardless of their origin and the feeding status of mice. This
is exemplified in adult rodents, in which it is fasting that
up-regulates UCP3 mRNA expression in response to the rise
in circulating FFA, in this case derived from lipolysis of
stored triacylglycerols in white adipose tissue (7).
Acute treatment of adults or neonates with fibrates, drugs
capable of activating peroxisome proliferator-activated re-
ceptor- (PPAR) or PPAR plus PPAR (also known as
PPAR) were shown to mimic the effects of fatty acids on
UCP3 gene expression in skeletal muscle (6, 8). Studies on the
transcriptional control of the human UCP3 gene established
that both PPAR and PPAR can activate UCP3 gene tran-
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scription and mediate fatty acid effects through a PPAR-
responsive element in the proximal region of the promoter
(9). However, PPAR is more potent than PPAR in trans-
activating the human UCP3 gene promoter, and in rodents,
Wy14,643, a PPAR-specific activator, was also capable of
maximal induction of UCP3 mRNA expression (10, 11). This
led to the proposal that PPAR could be the preferential
mediator of UCP3 gene activation in response to fatty acids.
In contrast, studies using myogenic cell lines differentiated
in culture, such as C2C12 or L6 cells, indicated that the UCP3
gene was particularly sensitive to PPAR agonists. However,
the relevance of these observations in relation to UCP3 gene
regulation in vivo is unclear considering the abnormal re-
pression in PPAR expression in these cell models with
respect to skeletal muscle (10).
Mice with a targeted disruption of the PPAR gene
(PPAR-null) provide a unique tool to establish the involve-
ment of this nuclear receptor in the control of UCP3 gene
expression in vivo in response to fatty acids. Previous reports
have shown that basal expression and responsiveness of the
UCP3 gene to induction by fasting in adults is unaltered in
skeletal muscle of PPAR-null mice, but it is down-regulated
in heart (12–14). In the present study, we report that PPAR
is required for the induction of UCP3 gene in response to
milk intake in both skeletal muscle and heart from neonatal
mice. This indicates that the compensatory mechanisms to
mediate fatty-acid-dependent responsiveness of the UCP3
are activated during skeletal muscle development, whereas
they are never able to compensate the absence of PPAR in
heart or in neonatal muscle.
Materials and Methods
Materials
Oleic acid, Wy14,643 (pirinixic acid), phytanic acid, GW501516, and
bezafibrate were obtained from Sigma Chemical Co. (St. Louis, MO).
Rosiglitazone was from Cayman (Ann Arbor, MI). AGN 194204 was a
kind gift from Dr. R. Chandraratna (Allergan, Irvine, CA).
Animals
The care and use of mice were in accordance with the European
Community Council Directive 86/609/EEC and approved by the Ex-
perimental Animal Ethics Committee of the University of Barcelona. For
studies in PPAR-null mice, heterozygous females carrying the corre-
sponding targeted deletion (15) were mated with heterozygous males,
and the day of gestation was determined by the presence of vaginal
plugs. For studies in neonates, pups were studied at birth (considered
to be the time at which pups had been born but had not yet started
suckling) and 8 and 16 h after birth. In adult mice, the effects of fasting
were determined by food withdrawal for 30 h. Mice were killed by
decapitation, and blood was collected into heparinized tubes and cen-
trifuged to obtain plasma. Hearts and whole muscle from the leg in
neonates and gastrocnemius muscle from adult mice were extracted and
frozen in liquid nitrogen. Fed and fasted animals, as well as wild-type
compared with homozygous gene-disrupted mice, were taken from the
same litter in each experiment, and at least three different litters per
experiment were analyzed.
Quantitative real-time RT-PCR
Total RNA was extracted from heart and skeletal muscle using Tri-
pure (Roche, Indianapolis, IN). The quality and concentration of the
RNA was determined by measuring the absorbance at 260 and 280 nm,
and the RNA integrity was confirmed by electrophoresis in agarose/
MOPS gel. The RNA was treated with DNase I to remove genomic DNA
(DNA-free; Ambion, Austin, TX). RT was performed in 20 l, using
random hexamer primers (Applied Biosystems, Foster City, CA) and 0.5
g RNA. PCR were conducted in duplicate for increased accuracy. Each
25l of reaction mixture contained 1l cDNA, 12.5l TaqMan Universal
PCR Master Mix (Applied Biosystems), 250 nm probes, and 900 nm
primers from Assays-on-Demand Gene Expression Assay Mix or As-
says-by-Design Gene Expression Assay Mix (Applied Biosystems). The
TaqMan Gene Expression Assays used were as follows: UCP3,
Mm00494074_m1; PPAR, Mm 00440939_m1; carnitine palmitoyl trans-
ferase Ib (CPT-Ib), Mm00487200; CPT-II, Mm00487202; medium-chain
acyl-CoA dehydrogenase (MCAD), Mm00431611; peroxisome prolif-
erator-activated receptor-coactivator 1 (PGC-1), Mm00447183;
UCP2, Mm00495907; pyruvate dehydrogenase kinase-4 (PDK4),
Mm00443325_m1; and 18S rRNA, Hs99999901_s1. Primers and probe for
the detection of PPAR were designed (Custom TaqMan Gene Expres-
sion Assays; Applied Biosystems), and the sequences were GCCCCG-
GAGCTCAATGG (forward) and TGGTCCAGCAGGGAGGAA (re-
verse) and the FAM-labeled probe was CTGTGCAGACCTCTCC. The
amplification was performed as follows: 2 min at 50 C, 10 min at 95 C,
and then 40 cycles each at 95 C for 15 sec and 60 C for 60 sec in the
ABI/Prism 7700 Sequence Detection System. Controls with no RNA,
primers, or reverse transcriptase were included in each set of experi-
ments. Each sample was run in duplicate, and the mean value of the
duplicate was used to calculate the mRNA expression of the gene of
interest and the housekeeping reference gene (18S rRNA). The amount
of the gene of interest in each sample was normalized to that of the
reference control using the comparative (2CT) method following the
manufacturer’s instructions.
Immunoblot assay of UCP3 protein levels
Mitochondrial preparations were obtained from neonatal muscle as
already reported (8). Samples of mitochondrial protein were mixed with
equal volumes of 2 SDS loading buffer, incubated at 90 C for 5 min,
and subjected to SDS-PAGE (12% wt/vol gel). Protein (40 g) was
transferred to polyvinylidene difluoride membranes, and immunode-
tection was performed using a rabbit affinity-pure UCP3 antiserum
(Chemicon AB3046; Chemicon, Temecula, CA). It was used at a 1:1000
dilution, and detection was achieved by the use of a horseradish-per-
oxidase-coupled antirabbit secondary antibody (sc-2004; Santa Cruz
Biotechnology, Santa Cruz, CA) and an enhanced chemiluminescence
(ECL) detection kit (Amersham, Piscataway, NJ). Blots were stripped
and probed with an antibody for subunit IV of cytochrome c oxidase
(A-6409; Molecular Probes, Eugene, OR). The sizes of the proteins were
estimated using protein molecular mass standards (Bio-Rad, Richmond,
CA).
Plasma metabolites
Plasma FFA levels were quantified using a colorimetric acyl-CoA
synthase and acyl-CoA oxidase-based method (NEFA C; Wako Chem-
icals, Neuss, Germany). Plasma glucose levels were determined with a
glucose-oxidase-based test (Accutrend; Roche). Plasma -hydroxybu-
tyrate levels were quantified using a spectrophotometric -hydroxybu-
tyrate dehydrogenase-based assay (Sigma).
Cell culture and transient transfection assays
Myoblastic L6 cells were obtained from American Type Culture Col-
lection (Rockville, MD) and were grown in DMEM containing 10% fetal
bovine serum. Transfection experiments were carried out in L6 cells at
50% confluence by using FuGene6 Transfection Reagent (Roche) and
were performed according to the manufacturer’s instructions. For L6
transfection, each point was assayed in triplicate in a six-well plate. Each
transfection contained 1.5 g of the plasmid 2mUCP3-Luc in which the
region from1946 to 60 of the mouse UCP3 gene drives the expression
of the cDNA for firefly (Photinus pyralis) luciferase, as reported elsewhere
(16). The plasmid 2mUCP3-PPREmut-Luc, containing point mutations
at the putative peroxisome proliferator response element (CC instead of
AG at sites 51 and 50, G instead of C at site 45, and TA instead of
GG at sites 43 and 42), was generated using the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA) and checked by direct
DNA sequencing. When indicated, transfection assays contained also 0.3
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g of the mammalian expression vectors pCMV-MyoD (17), pRSV-
RXR (18), pSG5-PPAR (19), pSG5-PPAR, and pSG5-PPAR (20) and
3 ng pRL-CMV (Promega, Madison, WI), an expression vector for the sea
pansy (Renilla reniformis) luciferase used as an internal transfection con-
trol. Cells were incubated for 48 h after transfection, and when indicated,
cells were treated for 24 h before harvest with or without 10 m
Wy14,643, 100 m bezafibrate, 1 m GW501516, 1 m AGN194204, 30
m phytanic acid, 10 m rosiglitazone, and 500 m oleic acid.
Firefly luciferase and Renilla luciferase activities were measured in a
Turner Designs Luminometer (model TD20/20) using the Dual Lucif-
erase Reporter assay system kit (Promega). Homogenates from cells
were prepared with 500 l passive lysis buffer (Promega). Cells were
lysed in agitation for 15 min, and 20 l of homogenate was used for
measurement. Luciferase activity elicited by UCP3 promoter constructs
was normalized for variation in transfection efficiency using Renilla
luciferase as an internal standard.
EMSA
The cDNAs for mouse PPAR and PPAR and human retinoid X
receptor- (RXR) were transcribed and translated in vitro using the
TNT Quick-Coupled Transcription/Translation Systems (Promega).
The sequence of the double-stranded oligonucleotide used in EMSA
corresponds to positions 58 to 25 of the mouse UCP3 gene (see Fig.
4B for the sequence). The 32P-labeled oligonucleotide (10,000–20,000
cpm) was incubated for 30 min at 25 C with 5 l of in vitro-transcribed/
translated proteins. Reactions were carried out in a volume of 20 l
containing 10 mm Tris-HCl (pH 8.0), 0.05% Nonidet P-40, 1 mm dithio-
threitol, 40 mm KCl, 6% glycerol, and 2 g of poly(dI)(dC). Samples
were analyzed by electrophoresis at 4 C in nondenaturing 5% poly-
acrylamide gels in 0.5TBE (44.5 mmTris, 44.5 mm borate, 1 mmEDTA).
The specificity of the binding was determined by including 100-fold
molar excess of unlabeled oligonucleotide as competitor.
Chromatin immunoprecipitation (ChiP) assay
L6 cells were transfected with 2mUCP3-Luc (containing 1946 bp of the
promoter) or 2mUCP3-PPREmut-Luc in the presence of PPAR expres-
sion vector and treated with oleic acid. ChiP was performed basically as
described elsewhere (16). The precleared chromatin solutions were in-
cubated overnight at 4 C with 2 g anti-PPAR antibody (Santa Cruz
sc-1983) or an equal amount of an unrelated Ig (Santa Cruz sc-9314).
DNA obtained after phenol-chloroform extraction was used for PCR
analysis. The primers used for the amplification of the promoter region
containing the DR-1 element are CCGTCTTCTCCTCTCCCCTC (for-
ward) and GTTGTCTCTGCTGTCCCTGG (reverse).
Statistical analysis
Where appropriate, statistical analysis was performed by Student’s t
test; significance is indicated in the text.
Results
Differential regulation of UCP3 mRNA expression
in heart and skeletal muscle in adult wild-type and
PPAR-null mice
To analyze the effects of the lack of expression of PPAR
in skeletal muscle on the regulation of UCP3 gene, UCP3
mRNA levels were measured in gastrocnemius skeletal mus-
cle in adult PPAR-null mice in comparison with their con-
trol littermates (Fig. 1A). The results showed that under fed
conditions, UCP3 mRNA levels were similar between both
genotypes. The increase in UCP3 mRNA in response to 30 h
of starvation was also similar in control and PPAR-null
mice (around 5-fold). The increase of UCP3 mRNA levels
resulting from starvation was also not impaired in tibialis
anterior or soleus muscles from PPAR-null mice (data not
shown).
UCP3 mRNA levels were analyzed in heart under the
same experimental conditions. UCP3 mRNA abundance was
significantly reduced (around 40%) in fed PPAR-null mice
with respect to fed controls (Fig. 1B). When mice were
starved for 30 h, the levels of UCP3 mRNA in heart increased
more than 7-fold in controls, whereas in PPAR-null mice,
the induction was significantly lower with respect to fed
PPAR-null mice (around 5-fold), and the total amount of
UCP3 mRNA was just 30% of the levels reached in the heart
of the starved control littermates. These findings are similar
to other reports (12, 13) and had been interpreted either as
indicating a minor role for PPAR in the control of skeletal
muscle UCP3 gene expression in vivo or as evidence of the
existence of compensatory mechanisms acting preferentially
in muscle to maintain normal regulation of UCP3 gene
expression.
To analyze the alterations in circulating metabolites re-
lated to energy metabolism, glucose, FFA, and ketone bodies
(-hydroxybutyrate) were determined in plasma (Table 1).
Although glucose levels were similar in wild-type and
PPAR-null mice in fed conditions and the levels of glucose
decrease in both genotypes because of starvation, in PPAR-
null mice, the levels of glucose were statistically lower than
in wild-type mice. FFA levels were similar under fed con-
FIG. 1. UCP3 mRNA levels in skeletal muscle and heart from wild-
type and PPAR-null adult mice. Eight-week-old mice were used in
basal conditions (fed) or under 30 h of starvation (fasted). Gastroc-
nemius skeletal muscle or heart was isolated, and UCP3 mRNA
expression was analyzed by quantitative RT-PCR as described in
Materials andMethods.Bars indicate themean SEM of six to 10mice
per group coming from at least three different litters. Data are shown
as fold induction with respect to values in wild-type fed mice. Sig-
nificant differences between fed and fasted mice are shown: *, P 
0.05; **, P  0.01; comparison between wild-type and PPAR-null
mice: #, P  0.05.
Pedraza et al. • PPAR Control of UCP3 Gene Endocrinology, October 2006, 147(10):4695–4704 4697
 at Univeristat de Barcelona. Biblioteca on March 3, 2009 endo.endojournals.orgDownloaded from 
ditions in both genotypes, but in response to starvation, FFA
from PPAR-null were significantly higher than in wild-type
mice.-Hydroxybutyrate levels showed no differences in fed
conditions between wild-type and PPAR-null mice. As ex-
pected, -hydroxybutyrate levels increased in response to
starvation, but this response was strongly impaired in
PPAR-null mice, being 60% less than that in their wild-type
littermates. The pattern of alterations in the metabolic re-
sponse to starvation in PPAR-null mice is in agreement with
previous reports on the characterization of the phenotype of
these mice (21, 22).
UCP3 mRNA expression in skeletal muscle and heart
depends on PPAR during the perinatal period
To study the role of PPAR on UCP3 gene regulation in
the perinatal period, hind-limb muscle and heart were ob-
tained from wild-type and PPAR-null mice just after birth
(0 h, no suckling) and at 8 and 16 h after birth, with pups
suckling (Fig. 2A, left). As expected, the levels of UCP3
mRNA in skeletal muscle of wild-type mice increased rap-
idly after birth, 8-fold after 8 h, and remained high 16 h later.
In PPAR-null mice, UCP3 mRNA levels increased to a mi-
nor extent; they were just 2-fold and 3-fold higher 8 and 16 h
after birth, respectively.
The reduction in UCP3 gene expression in muscle from
PPAR-null neonates occurred also at the protein level (Fig.
2A, right). The regulation of UCP3 by PPAR in heart was
similar to adults (Fig. 2B). In wild-type mice, 16 h after birth,
UCP3 mRNA levels increased 5-fold with respect to pups at
birth. In the PPAR-null pups, the increase observed on
UCP3 mRNA at 16 h was just 2-fold, significantly lower than
in wild-type mice. These results indicate a major impact of
the lack of PPAR in skeletal muscle of neonatal mice with
respect to adults, whereas the behavior of UCP3 gene ex-
pression in heart was similarly impaired as in adult PPAR-
null mice.
The levels of glucose, FFA, and ketone bodies were also
measured in plasma of wild-type and PPAR-null mice 16 h
after birth (Table 2). Glucose and FFA levels did not show any
statistically significant difference between both groups of
mice, whereas the levels of the -hydroxybutyrate showed a
remarkable 75% reduction in PPAR-null with respect to
wild-type pups. Unaltered levels of FFA in PPAR-null mice
indicate that there is no impairment in their suckling behav-
TABLE 1. Serum metabolites in adult wild-type and PPAR -null mice: effects of fasting
Fed Fasted
Wild type PPAR-null Wild type PPAR-null
Glucose (mM) 9.8  1.1 8.5  1 4.2  0.6b 2.8  0.3b
FFA (M) 650  85 770  20 825  27a 1558  102b,c
-Hydroxybutyrate (mM) 0.2  0.01 0.2  0.04 1.2  0.1a 0.39  0.14c
Statistical significance of differences between fed and fasted mice is shown as a P  0.05 and b P  0.01 and that between wild-type and
PPAR -null mice at any feeding status as c P  0.05.
FIG. 2. UCP3 gene expression in skeletal muscle and heart
from wild-type and PPAR-null neonates. Pups were stud-
ied immediately after birth (0 h, no feeding) or 8 and 16 h
after birth. Quantitative RT-PCR was performed to assess
UCP3 mRNA levels in hind limb and heart from neonates.
Results are the mean  SEM of four to six mice per group
coming from at least three different litters. Data are shown
as fold induction with respect to values in wild-type, 0-h-old
pups. Significant differences between values at 8 or 16 h
after birth with respect to values at 0 h are shown: *, P 
0.05; **, P  0.01; comparison between wild-type and
PPAR-null mice at every time point of development: #,P
0.05. A, Right, A representative immunoblot of equal
amounts (40 g) of skeletal muscle mitochondrial protein
from 16-h-old wild-type and PPAR-null mice probed with
UCP3 and subunit IV of cytochrome c oxidase (COX IV)
antibodies (see Materials and Methods). Data are repre-
sentative of three independent experiments.
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ior, because FFA in neonatal blood are highly dependent on
the extent of milk intake. Thus, lowered UCP3 mRNA in
PPAR-null pups could not be caused by the exposure of
skeletal muscle and heart to lower levels of circulating FFA
and should be caused by a lack of responsiveness of the
tissues. Similarly to adults, PPAR-null pups showed low-
ered circulating ketone bodies, which is indicative of a re-
duced hepatic oxidation of fatty acids, in this case coming
from milk intake. This is in agreement with the reported
impairment in gene expression for ketogenic enzymes in
perinatal liver of PPAR-null mice (23).
PPAR and PPAR can mediate fatty-acid-dependent
activation of mouse UCP3 gene transcription
We undertake the analysis of the responsiveness of the
mouse UCP3 gene transcription to fatty acids and the in-
volvement of PPARwith respect to other nuclear receptors.
For this purpose, a construct containing around 2 kb of the
mouse UCP3 promoter fused to luciferase reporter gene was
transiently transfected to L6 myogenic cells. In the absence
of cotransfected MyoD, the mouse UCP3 gene promoter
showed a very low activity and was not sensitive to induction
by fatty acids or PPAR and PPAR agonists (Fig. 3). In the
presence of cotransfected MyoD, the mouse UCP3 promoter
activity increased around 15-fold and became sensitive to the
induction by fatty acids. Thus, in the presence of MyoD,
induction of UCP3 mouse promoter by oleic acid was ob-
served when PPAR or PPAR but not PPAR was cotrans-
fected. In addition, in the presence of PPAR, treatment of
the cells with PPAR agonists (Wy 14,643 and bezafibrate)
increased the activity of the promoter similarly to what is
observed for oleic acid. Also, the addition of PPAR agonists
(GW 501516 or bezafibrate), when cotransfected with PPAR,
increased the activity of the promoter significantly. Because
the induction by fatty acids could be mediated by RXR (24),
parallel experiments were performed cotransfecting this nu-
clear receptor and treating the cells with oleic acid and also
with RXR agonists (phytanic acid and AGN 194204). The
specific RXR ligand AGN 194204 caused a small but signif-
icant induction of the UCP3 promoter. No statistically sig-
nificant effects due to oleic or phytanic acid were observed,
indicating that the ligand-dependent activation of RXR
alone, via a potential homodimer or heterodimer with re-
ceptors other than PPARs, is not mediating mouse UCP3
regulation in response to fatty acids, at least in vitro.
Sequence analysis of the 5 noncoding region of the mouse
UCP3 gene indicated the presence at position 51/38 of a
one-base-spaced direct repeat (AGGTTTCAGGTCA) identi-
TABLE 2. Serum metabolites in neonatal wild-type and
PPAR -null mice
Wild type PPAR -null
Glucose (mM) 3.17  0.54 2.98  0.81
FFA ( M) 746  103 946  245
 -Hydroxybutyrate (mM) 0.70  0.38 0.18  0.09a
Serum was obtained from 16-h-old pups. Statistical significance of
differences between wild-type and PPAR-null mice are shown as
a P  0.01.
FIG. 3. Mouse UCP3 promoter activity
in response to oleic acid in muscle cells.
Effects of PPARs and RXR. Transient
transfection assays of the 2mUCP3-Luc
construct, containing 2 kb of the pro-
moter region of mouseUCP3 gene fused
to luciferase reporter gene, were per-
formed in L6 muscle cells. When indi-
cated, 0.3 g MyoD expression vector
was cotransfected and also, when indi-
cated, with 0.3 g PPAR, -, or - and
RXR expression vectors. Treatments
with agonists were performed for 24 h.
Results are the mean  SEM of at least
three independent experiments per-
formed in triplicate. All samples co-
transfected with MyoD expression
vectors show significantly higher lucif-
erase activity than non-cotransfected
ones (P 0.001). Significant differences
resulting from addition of the agonists
respect to their relative controls are
shown: *, P  0.05; **, P  0.01.
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cal to that previously identified in the human UCP3 pro-
moter to mediate fatty acid effects through PPARs (9). EMSA
analysis revealed that this site was capable of a high-affinity
binding to PPAR/RXR and PPAR/RXR heterodimers but
not to RXR alone (Fig. 4A).
A version of the plasmid construct containing the 2-kb
mouse UCP3 gene promoter including point mutations at the
51/38 region (Fig. 4B) was obtained. The mutations in-
troduced disrupted the capacity of PPAR/RXR and
PPAR/RXR to bind this site as determined by EMSA (not
shown). This mutated construct lost completely the capacity
of PPAR-mediated activation by oleic acid, and it was to-
tally unresponsive to the PPAR-specific activator Wy 14,643
(Fig. 4C). In addition, the mutated construct showed also a
reduced capacity of being activated by oleic acid in the pres-
ence of transfected PPAR, although some extent of activa-
tion remained. The same behavior was observed for the
PPAR-specific activator GW 501516.
Experiments of ChiP were performed to corroborate the
binding of PPAR to this region (Fig. 4D). Nuclear extracts
from L6 where obtained from cells transfected either with
2mUCP3-Luc or 2mUCP3-PPREmut-Luc. Results showed an
enrichment of the PCR product of the region containing
the DR-1 region when the PPAR antibody was added to
the extracts from the cells transfected with the wild-type
construct. In contrast, no enrichment was observed when
the antibody was added in cells transfected with the mu-
tated construct. These results indicate that PPAR binds in
vivo the DR-1 located at51/38 of the mouse UCP3 gene
promoter.
FIG. 4. A proximal site binding PPARs
is involved inmediating the responsive-
ness of the mouse UCP3 promoter to
oleic acid and PPAR agonists in muscle
cells. A, EMSA of the binding of in vitro
translated PPAR and - and RXR.
Arrows indicate the specific retarded
bands due to PPAR/RXR and PPAR/
RXR heterodimers. B, Sequence of the
mouse UCP3 promoter at58/25, let-
ters at the bottom indicate the pointmu-
tation changes introduced to suppress
PPAR binding. C, Transient transfec-
tion assays of the 2mPPREmut-UCP3-
Luc construct in comparison with the
wild-type 2mUCP3-Luc. Plasmids were
transiently transfected into L6 cells as
in Fig. 3. Transfections included 0.3 g
MyoD expression vector and, when in-
dicated, 0.3 g PPAR or PPAR ex-
pression vectors. Treatments with ago-
nists were performed for 24 h. Results
are the mean  SEM of at least three
independent experiments performed in
triplicate and are expressed as fold ac-
tivity respect to basal activity in the
absence of PPARs or agonists. #, Sta-
tistically significant (P  0.05) differ-
ences resulting from oleic acid or PPAR
agonists in every construct; *, those be-
tween constructs at any experimental
condition. D, ChiP analysis of PPAR
binding to the mouse UCP3 gene pro-
moter. ChiP was performed on L6 cells
transfected with the 2mUCP3-Luc
or 2mUCP3-PPREmut-Luc constructs.
The arrow indicates the PCR product
from mouse UCP3 promoter. Con, No
DNA; Con, positive plasmid amplifi-
cation. The results are representative of
three independent experiments.
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Gene expression of PPAR and PPAR in neonatal and
adult skeletal muscle and heart
The results above suggest that the sensitivity of the UCP3
gene transcription to PPAR can constitute a major mecha-
nism for compensation of the lack of PPAR. However, this
mechanism appears not to be operational in heart but to be
enough for compensating UCP3 mRNA expression at least in
adult skeletal muscle. PPAR gene expression studies were
undertaken in wild-type and PPAR-null mice in the situ-
ations studied before (Fig. 5). In skeletal muscle, PPAR
mRNA levels were slightly decreased in neonates 16 h after
birth. No differences were observed between wild-type and
PPAR-null either at birth or 16 h later. PPARmRNA abun-
dance was similar in adult and neonatal skeletal muscle.
PPAR mRNA expression was induced as a consequence of
starvation in skeletal muscle from wild-type mice and, to a
minor extent, in PPAR-null mice. In heart, there were also
no differences in PPAR mRNA levels between wild-type
and PPAR-null neonates. Adults showed a higher expres-
sion of PPAR mRNA with respect to neonates. Starvation
caused a slight decrease in PPARmRNA levels in wild-type
mice. Thus, results indicate that there were no major changes
in PPAR mRNA expression resulting from the lack of
PPAR in skeletal muscle and heart.
Gene expression analysis of PPAR revealed that neonatal
skeletal muscle expressed around 3-fold more PPAR
mRNA than adult skeletal muscle. This difference did not
occur in heart. Starvation of adult mice did not cause changes
in PPAR mRNA levels either in skeletal muscle or in heart.
The study was extended to determine PGC-1 mRNA
expression during development. PGC-1 mRNA relative
abundance in muscle from neonatal (16-h-old) pups was
1.7  0.3-fold with respect to that in adult skeletal muscle,
and in neonatal heart, it was 2.7 0.4-fold with respect to that
FIG. 5. PPAR mRNA and PPAR
mRNA levels in skeletal muscle and
heart from wild-type and PPAR-null
neonates and adults. Gastrocnemius
skeletal muscle (adults) or hind-limb
muscle (neonates) and heart were dis-
sected, and the mRNA levels for PPAR
and PPAR were analyzed by quanti-
tative RT-PCR as described in Materi-
als and Methods. Bars indicate the
mean SEM of four to 10mice per group
coming from at least three different lit-
ters. Results are expressed as fold in-
duction with respect to values in neo-
natal (16-h-old) mice. For every
genotype, significant differences be-
tween neonates (16 h old) and adults
either fed or fasted are shown: , P 
0.05; *, P  0.05 for significant differ-
ences due to fasting in adults; #, P 
0.05 for those between wild-type and
PPAR-null mice.
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in adult heart. Similar findings have been reported in cardiac
mouse development (25). Levels of PGC-1 transcripts were
higher in heart than in skeletal muscle, in both neonates and
adults. This is in agreement with previous reports in adult
mice (26). PGC-1 transcript levels were not significantly
modified in muscle or heart from PPAR-null mice, either in
neonates or in adults (not shown).
Differential effects of PPAR invalidation on the expression
of PPAR and PPAR target genes
To determine whether the reduction in UCP3 mRNA ex-
pression in neonatal muscle and heart from PPAR-null mice
corresponds to a general impairment in the expression of
PPAR target genes, additional gene expression analysis was
performed on neonates. Genes involved in fatty acid catab-
olism, especially those whose transcripts were up-regulated
in transgenic mouse models of overexpression of PPAR in
skeletal muscle, were analyzed (27). In wild-type mice, tran-
script levels for UCP2, CPT-II, and PDK4 were dramatically
up-regulated in heart from 16-h-old, suckling pups, with
respect to the those before initiation of suckling (0 h),
whereas no postnatal induction was observed for CPT-I or
MCAD mRNA. In skeletal muscle, only UCP2 mRNA levels
showed postnatal induction. In skeletal muscle and heart
from PPAR-null neonates, the postnatal induction of UCP2
mRNA was impaired (Fig. 6). CPT-II mRNA and PDK4
mRNA levels were down-regulated only in postnatal heart
and unaffected in muscle. No effects were observed in
CPT-I or MCAD mRNA levels in skeletal muscle or heart
from PPAR-null mice, in accordance with the low sensi-
tivity of these genes to PPAR-dependent regulation in vivo
(27). UCP2 mRNA, the only transcript lowered in postnatal
muscle, was not significantly altered in skeletal muscle from
adult PPAR-null mice either in fed (1.2 0.4 1-fold change)
or in fasted conditions (1.5  0.7-fold change). However, in
heart, UCP2 mRNA levels were significantly reduced in
fasted (0.23 0.1-fold change with respect to wild-type, P
0.05) but not in fed (0.8  0.2-fold change with respect to
wild-type) PPAR-null mice, similarly to UCP3 mRNA.
Discussion
In the present study, we describe a differential impact of
the lack of PPAR on UCP3 gene expression depending on
the tissue and the stage of development. Thus, UCP3 gene
expression in heart is systematically impaired both in neo-
nates and adults, either fed or fasted, when mice lack PPAR.
In contrast, skeletal muscle from PPAR-null adult mice
shows unaltered UCP3 gene expression in basal conditions
and in response to starvation. However, because the increase
in FFA concentration is considered the signal inducer for
UCP3 mRNA expression in response to fasting in muscle, it
is noteworthy that the higher increase in FFA levels observed
in fasted PPAR-null mice results just in an equal induction
of UCP3 mRNA with respect to wild-type mice. Previous
data in rodents under different physiological and experi-
mental situations indicate a very close association between
the levels of circulating FFA and skeletal muscle UCP3
mRNA levels (4) The differential relationship between FFA
and UCP3 mRNA levels in PPAR-null mice may indicate
that despite UCP3 mRNA levels being preserved, there is
some extent of impairment or resistance in the responsive-
ness of UCP3 gene expression to fatty acids because of the
lack of PPAR.
In contrast with adults, the UCP3 mRNA induction in
neonates as a consequence of initiation of suckling is severely
impaired not only in heart but also in skeletal muscle from
PPAR-null mice. Lowered UCP3 mRNA in PPAR-null
pups is not caused by lower levels of circulating FFA, which
were unaltered. Thus, it appears that PPAR is particularly
required for UCP3 regulation in response to fatty acids in the
neonatal period.
FIG. 6. Gene expression analysis of genes involved in fatty acid me-
tabolism in skeletalmuscle and heart fromwild-type and PPAR-null
neonates. mRNA was isolated from hind limb and heart from neo-
nates just after birth (0 h) or after 16 h being with their mothers (16
h), and quantitative RT-PCRwas performed as described inMaterials
andMethods to analyze the levels of expression of UCP2, PDK4, CPT
I, CPT II, and MCAD. Results are shown as fold induction with
respect to values in wild-type mice at 0 h, and bars indicate the
mean  SEM of four to six mice per group. For every genotype, sig-
nificant differences between neonates at 0 and 16 h are shown: *, P
0.05; #, significant differences between wild-type and PPAR-null
mice at P  0.05.
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The present findings on the transcriptional regulation of
the mouse UCP3 gene promoter indicate a similar behavior
with respect to the human promoter (9); it is dependent on
MyoD, and responsiveness to fatty acids can be mediated by
PPAR or PPAR. This is in contrast with the responsiveness
of the UCP3 gene to thyroid hormones, which is remarkably
different between humans and mice (16). In fact, despite the
large divergence in overall promoter sequence and func-
tional structure between humans and mice (28), the one-
base-spaced direct repeat previously identified in the human
UCP3 promoter to mediate fatty acid effects through PPARs
is completely conserved in the mouse proximal promoter
region at position 51/38. We found that, like in humans,
it binds PPAR/RXR and PPAR/RXR heterodimers as well
as being involved in mediating the responsiveness to fatty
acids via PPARs. This identical sequence is also present in the
proximal region of the UCP3 genes from all the other mam-
malian species in which the 5 noncoding region sequence is
available in databases (accession number AF168989 for Rat-
tus norvegicus, AY523564 for Phodopus sungorus, Nw876273
for Canis familiaris, and Nw92833 for Bos taurus). However,
it should be noted that in contrast with PPAR, some re-
sponsiveness to PPAR remains in mutated constructs at this
site, thus indicating the possibility of additional mechanisms
of PPAR-dependent activation of the mouse UCP3 gene.
Overall, the present findings indicate that the requirement
of PPAR for the regulation of UCP3 gene expression is
tissue and development specific, and PPAR plays an espe-
cially critical role in the perinatal period. Compensatory
mechanisms other than PPAR activation for fatty-acid-de-
pendent regulation of UCP3 gene transcription are present in
adults to ensure normal UCP3 mRNA expression when mus-
cle is exposed to high levels of circulating FFA, but they are
not active in adult heart or in the heart and skeletal muscle
during the neonatal period. Although other mechanisms of
fatty-acid-dependent regulation of transcription cannot be
excluded, PPAR is a likely candidate to mediate this alter-
ative pathway of regulation of UCP3 gene expression, con-
sidering its activity on UCP3 gene promoter regulation in
response to fatty acids. However, PPAR-mediated compen-
satory mechanisms of control of UCP3 gene expression
would not require up-regulation of PPAR mRNA levels,
which are unaltered in different tissues and developmental
stages of mice lacking PPAR. However, the high expression
of PPAR mRNA in neonatal skeletal muscle with respect to
adults may be consistent with a more critical requirement of
PPAR to mediate gene expression responsiveness to fatty
acids in muscle during the perinatal period.
The fact that a gene such as UCP2, sharing dual PPAR-
and PPAR-dependent regulation like UCP3 (27, 29–31), also
shows altered gene expression in heart and in neonatal mus-
cle but not in adult muscle supports the notion of a lack of
compensatory effects of PPAR-dependent pathways in
muscle from neonates. However, the unaltered expression of
the transcripts for PDK4 and CPT-II, which are also targets
of both PPAR and PPAR regulation in adult muscle (27, 29,
31), suggests other potential mechanisms to explain the tis-
sue- and development-dependent impact of PPAR defi-
ciency in the UCP3 and UCP2 genes. Only those genes in-
volved in lipid catabolism whose expression is significantly
induced in muscle or heart when milk intake begins were
affected in neonates by the lack of PPAR. It cannot be
excluded that the differential origin and composition of fatty
acids stimulating gene expression of UCP3 and UCP2 genes
when they come from milk (neonates) or from lipolysis in
white fat (starved adults) act differently on the PPAR- and
PPAR-dependent mechanisms of regulation of gene expres-
sion in muscle and heart. Another aspect to be considered is
the potential differential requirement of coactivators in mus-
cle and heart from neonates with respect to adults to mediate
PPAR-dependent regulation of UCP3 gene and other genes
involved in lipid catabolism. Our present data do not indi-
cate lower levels of PGC-1, at least at the transcript level, in
neonates with respect to adults, but the opposite. P300, an-
other PPAR coactivator involved in UCP3 promoter regu-
lation in humans, has been reported to be more abundant in
neonates than in adults (32). PGC-1 and p300 expression are
higher in heart than in skeletal muscle at any time of devel-
opment. Thus, these data do not suggest that limiting
amounts of these coactivators could explain the specific im-
pairment of gene expression in skeletal muscle from PPAR-
null neonates or in heart with respect to muscle. However,
an extensive analysis of developmental regulation in muscle
and heart of the multiple coactivators of PPARs reported to
date should be undertaken to settle this issue.
On the other hand, although the precise physiological
function is still a matter of debate, UCP3 appears to be in-
volved in metabolic handling of fatty acids in muscle and
heart in a way that minimizes lipotoxicity and excessive
production of reactive oxygen species (33, 34). In fact, its
pattern of regulation reported here in relation to neonatal
development and PPAR-dependent pathways is shared in
muscle only by the other gene involved in similar functions,
UCP2. Genes involved in lipid catabolism but without rela-
tion to mitochondrial bioenergetics or reactive oxygen spe-
cies regulation, such as PDK4 or CPT-II, are altered in parallel
with UCP genes only in heart. In this sense, modulation of
UCP3 gene expression through drugs acting on PPARs could
influence muscle oxidative metabolism and would be ex-
pected to act in parallel upon UCP2 gene expression. UCP3
gene promoter studies described above as well as studies in
vivo using transgenic mice overexpressing PPAR or PPAR
in skeletal muscle indicate that both types of PPAR receptors
can induce UCP3 gene expression in adults (27, 29). Present
findings indicate that in other physiological situations such
as early development, UCP3 is much more dependent of
PPAR activation. Moreover, despite that UCP3 mRNA lev-
els are lower in heart than in skeletal muscle, recent data are
indicative of a relevant role of UCP3 in human heart in
relation to the partitioning of metabolic fuels (35), and
present results point to PPAR as the receptor unequivocally
mediating UCP3 gene regulation in response to fatty acids or
fibrates in rodent heart.
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